CD8
PD-1
PD-L1
circulating tumor cells
immune cells
immunosuppression
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
10
2018
accepted:
12
02
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
21
6
2019
Statut:
epublish
Résumé
Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed death ligand (PD-L)1 axis, this study was designed in order to evaluate whether there is a correlation between the levels of PD-1 Peripheral blood was obtained from 37 chemotherapy-naïve patients with metastatic NSCLC before treatment. PD-1 and PD-L1 expression was evaluated (1) on ICs with anti-tumor function (CD4 The presence of PD-1 The results of the current study, for first time, provide evidence for a possible interaction between ICs and CTCs in NSCLC patients
Sections du résumé
BACKGROUND
BACKGROUND
Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed death ligand (PD-L)1 axis, this study was designed in order to evaluate whether there is a correlation between the levels of PD-1
PATIENTS AND METHODS
METHODS
Peripheral blood was obtained from 37 chemotherapy-naïve patients with metastatic NSCLC before treatment. PD-1 and PD-L1 expression was evaluated (1) on ICs with anti-tumor function (CD4
RESULTS
RESULTS
The presence of PD-1
CONCLUSION
CONCLUSIONS
The results of the current study, for first time, provide evidence for a possible interaction between ICs and CTCs in NSCLC patients
Identifiants
pubmed: 31217824
doi: 10.1177/1758835919853193
pii: 10.1177_1758835919853193
pmc: PMC6563396
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835919853193Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Clin Cancer Res. 2003 Oct 1;9(12):4296-303
pubmed: 14555498
Clin Cancer Res. 2004 Aug 1;10(15):5094-100
pubmed: 15297412
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Cytometry A. 2004 Nov;62(1):46-53
pubmed: 15472900
Lancet. 2007 May 19;369(9574):1742-57
pubmed: 17512859
Clin Cancer Res. 2008 Aug 15;14(16):5013-21
pubmed: 18698019
Science. 2008 Sep 26;321(5897):1785-7
pubmed: 18818347
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Science. 2010 Feb 26;327(5969):1072-4
pubmed: 20185704
Int J Cancer. 2011 Feb 15;128(4):887-96
pubmed: 20473887
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Int J Cancer. 2011 Oct 1;129(7):1651-60
pubmed: 21128227
Curr Opin Immunol. 2012 Apr;24(2):207-12
pubmed: 22236695
Clin Lung Cancer. 2013 Mar;14(2):157-63
pubmed: 22868219
Tumori. 2012 Nov;98(6):751-5
pubmed: 23389362
Clin Cancer Res. 2013 Mar 1;19(5):1021-34
pubmed: 23460533
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Lab Invest. 2014 Jan;94(1):107-16
pubmed: 24217091
Front Oncol. 2014 Oct 14;4:271
pubmed: 25353007
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Trends Mol Med. 2015 Jan;21(1):24-33
pubmed: 25440090
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Oncotarget. 2015 Aug 28;6(25):20902-20
pubmed: 26041877
Mol Oncol. 2015 Nov;9(9):1773-82
pubmed: 26093818
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Front Oncol. 2015 Sep 22;5:207
pubmed: 26442219
J Mol Med (Berl). 2016 May;94(5):509-22
pubmed: 26689709
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Clin Cancer Res. 2016 Apr 15;22(8):1856-64
pubmed: 27084739
Sci Rep. 2016 Jul 01;6:28910
pubmed: 27363678
Ann Oncol. 2016 Oct;27(10):1940-6
pubmed: 27405322
PLoS One. 2016 Jul 26;11(7):e0159397
pubmed: 27459545
Oncoimmunology. 2016 Mar 28;5(6):e1165377
pubmed: 27471641
Sci Rep. 2016 Aug 24;6:31726
pubmed: 27553175
Onco Targets Ther. 2016 Aug 12;9:5023-39
pubmed: 27574444
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121
pubmed: 29383038